Compare OOMA & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OOMA | ALDX |
|---|---|---|
| Founded | 2003 | 2004 |
| Country | US | US |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 332.9M | 317.7M |
| IPO Year | 2015 | 2014 |
| Metric | OOMA | ALDX |
|---|---|---|
| Price | $11.49 | $4.98 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $19.00 | $9.50 |
| AVG Volume (30 Days) | 131.2K | ★ 723.7K |
| Earning Date | 03-09-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $114,490,000.00 | N/A |
| Revenue This Year | $7.80 | N/A |
| Revenue Next Year | $19.21 | $36.25 |
| P/E Ratio | $128.67 | ★ N/A |
| Revenue Growth | ★ 9.53 | N/A |
| 52 Week Low | $9.79 | $1.18 |
| 52 Week High | $15.09 | $7.19 |
| Indicator | OOMA | ALDX |
|---|---|---|
| Relative Strength Index (RSI) | 47.29 | 45.73 |
| Support Level | $11.28 | $4.91 |
| Resistance Level | $11.80 | $5.56 |
| Average True Range (ATR) | 0.44 | 0.35 |
| MACD | -0.04 | -0.06 |
| Stochastic Oscillator | 45.45 | 6.37 |
Ooma Inc is a communications services company. It is a smart software-as-a-service (SaaS) and unified communications platform that deliver voice and collaboration features including messaging, intelligent virtual attendants and video conferencing, and residential phone service provides PureVoice high-definition voice quality, advanced functionality and integration with mobile devices. Its services rely upon the following main elements: multi-tenant cloud service, on-premise devices, desktop and mobile applications, and calling platforms. It generates revenues from the sale of subscriptions and other services.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.